Want to see ANIK full AI Analyst Report?
Total Valuation
Anika Therapeutics has a market cap or net worth of $258.02M. The enterprise value is $187.52.
Market Cap$258.02M
Enterprise Value$187.52
Share Statistics
Anika Therapeutics has 13,382,966 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding13,382,966
Owned by Insiders4.99%
Owned by Institutions3.83%
Financial Efficiency
Anika Therapeutics’s return on equity (ROE) is -0.08 and return on invested capital (ROIC) is -6.48%.
Return on Equity (ROE)-0.08
Return on Assets (ROA)-0.06
Return on Invested Capital (ROIC)-6.48%
Return on Capital Employed (ROCE)-0.07
Revenue Per Employee480.08K
Profits Per Employee-46.30K
Employee Count235
Asset Turnover0.59
Inventory Turnover2.61
Valuation Ratios
The current PE Ratio of Anika Therapeutics is ―. Anika Therapeutics’s PEG ratio is 0.16.
PE Ratio―
PS Ratio1.22
PB Ratio0.96
Price to Fair Value0.96
Price to FCF31.59
Price to Operating Cash Flow43.32
PEG Ratio0.16
Income Statement
In the last 12 months, Anika Therapeutics had revenue of 112.82M and earned -10.88M in profits. Earnings per share was -0.76.
Revenue112.82M
Gross Profit63.81M
Operating Income-11.05M
Pretax Income-9.31M
Net Income-10.88M
EBITDA-3.58M
Earnings Per Share (EPS)-0.76
Cash Flow
In the last 12 months, operating cash flow was 5.98M and capital expenditures -5.42M, giving a free cash flow of 562.00K billion.
Operating Cash Flow5.98M
Free Cash Flow562.00K
Free Cash Flow per Share0.04
Dividends & Yields
Anika Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.94
52-Week Price Change119.84%
50-Day Moving Average15.16
200-Day Moving Average12.52
Relative Strength Index (RSI)46.69
Average Volume (3m)174.95K
Important Dates
Anika Therapeutics upcoming earnings date is Oct 29, 2026, After Close (Confirmed).
Last Earnings DateJul 29, 2026
Next Earnings DateOct 29, 2026
Ex-Dividend Date―
Financial Position
Anika Therapeutics as a current ratio of 4.72, with Debt / Equity ratio of 16.98%
Current Ratio4.72
Quick Ratio3.86
Debt to Market Cap0.18
Net Debt to EBITDA8.73
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Anika Therapeutics has paid 672.00K in taxes.
Income Tax672.00K
Effective Tax Rate-0.07
Enterprise Valuation
Anika Therapeutics EV to EBITDA ratio is -29.78, with an EV/FCF ratio of 24.43.
EV to Sales0.94
EV to EBITDA-29.78
EV to Free Cash Flow24.43
EV to Operating Cash Flow9.52
Balance Sheet
Anika Therapeutics has $38.41M in cash and marketable securities with $23.32M in debt, giving a net cash position of $15.10M billion.
Cash & Marketable Securities$38.41M
Total Debt$23.32M
Net Cash$15.10M
Net Cash Per Share$1.13
Tangible Book Value Per Share$9.33
Margins
Gross margin is 62.16%, with operating margin of -9.80%, and net profit margin of -9.64%.
Gross Margin62.16%
Operating Margin-9.80%
Pretax Margin-8.25%
Net Profit Margin-9.64%
EBITDA Margin-3.17%
EBIT Margin-8.25%
Analyst Forecast
The average price target for Anika Therapeutics is $21.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$21.00
Price Target Upside40.47% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-2.50%
EPS Growth Forecast93.57%